Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs CSX Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280.46 (market cap $39.89B), while CSX Corporation trades at $49.77 (market cap $91.81B). The key difference: CSX Corporation is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and CSX Corporation pays a 1.13% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CSX | |
|---|---|---|
Market Cap | $39.89B | $91.81B |
Sector | Health | Industrials |
52-Week High | $491.22 | $49.41 |
52-Week Low | $278.09 | $32.05 |
Enterprise Value | $38.15B | $110.04B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CSX trades at $49.41, slightly above the consensus price target of $48.21, with a 0.12% daily gain. The technical outlook is bullish based on moving averages, though RSI levels suggest overbought conditions. Recent earnings have shown mixed results, beating estimates in Q1 2026 but missing in Q4 2025, while revenue has declined from $14.9B in 2022 to $14.1B in 2025. The company maintains strong profitability with a 21.55% net income margin and recently announced a $0.14 dividend payable in June 2026.
The stock faces headwinds from declining revenue and high valuation multiples (P/E of 30.31), but analyst sentiment remains positive with 56.52% buy ratings. Key risks include freight demand volatility and elevated debt levels. Upside potential exists if operational improvements and margin expansion initiatives succeed, but investors should weigh rich valuations against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
